Skip to content

Partnership Opportunities

Why Partner with Us?

Although there is already an approved T cell engager drug for liquid tumors, there are no approved drugs for solid tumors. T cell engagers have dominated the industry thus far however, there have been major developments in NK engagers for use in immuno-oncology.

There are many challenges that need to be overcome and cell engaging drug developers are actively seeking partners who can provide solutions to these challenges. This is your opportunity to showcase your technology and expertise at the only meeting solely focused on cell engager drugs.

Whether you need to communicate exciting progress to the decision makers in the field, are looking to generate new business leads, or would like to understand what next-generation investments the market wants, you can rely on our ability to advise and deliver the right solution for you.

We will work with you to design a bespoke partnership package where you could:

Untitled design (9)

Position yourself as an industry thought leader - Now is your chance to get in front of your target key decision makers in the market and demonstrate your expertise through podium presentations, moderating panel discussions or interactive roundtables.

Untitled design (9)

Raise brand awareness - Increase your reach and exposure to new clients, customers and businesses through unique branding opportunities pre and post conference.

 

Untitled design (9)

Meet and network with industry pioneers - With a room full of drug developers looking to see how they can produce the safest cell engager drugs, fill your pipeline with new leads for 2020 through one-to-one meetings and networking opportunities.

Untitled design (9)

Generate commercial collaborations - Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event.

 

Untitled design (9)

Benefit from market intelligence - Discover what solutions and services pharmaceuticals and biotechs will be investing in to cell engager drugs on large scales in 2020 to enable you to match your solutions accordingly.